Barclays PLC Buys 86,677 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Barclays PLC grew its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 128.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 154,297 shares of the biopharmaceutical company's stock after acquiring an additional 86,677 shares during the period. Barclays PLC owned 0.26% of Vanda Pharmaceuticals worth $722,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Verition Fund Management LLC raised its position in Vanda Pharmaceuticals by 7.8% during the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company's stock valued at $189,000 after acquiring an additional 2,927 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Vanda Pharmaceuticals by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company's stock worth $2,796,000 after purchasing an additional 3,473 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 4,374 shares during the last quarter. Susquehanna Fundamental Investments LLC lifted its position in shares of Vanda Pharmaceuticals by 2.1% in the second quarter. Susquehanna Fundamental Investments LLC now owns 287,677 shares of the biopharmaceutical company's stock worth $1,625,000 after buying an additional 5,994 shares during the last quarter. Finally, ORG Wealth Partners LLC bought a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $40,000. 88.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

VNDA has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Vanda Pharmaceuticals in a research report on Monday, December 23rd. StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a report on Sunday. They set a "hold" rating for the company.

Insider Buying and Selling

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the company's stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the completion of the transaction, the director now directly owns 44,857 shares in the company, valued at approximately $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 8.90% of the stock is owned by company insiders.

Vanda Pharmaceuticals Stock Down 0.2 %

NASDAQ VNDA traded down $0.01 during midday trading on Thursday, hitting $4.44. The company had a trading volume of 457,850 shares, compared to its average volume of 512,968. The firm has a fifty day simple moving average of $4.86 and a two-hundred day simple moving average of $5.05. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.46 and a fifty-two week high of $6.75. The stock has a market cap of $258.90 million, a price-to-earnings ratio of -15.86 and a beta of 0.77.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.